Glympse Advances BioSensors for NASH and Other Protease-Mediated Diseases

Glympse Bio’s tunable biosensors are poised to be a game-changing diagnostic tool in 2021. These noninvasive biosensors report real-time biological changes for protease-mediated disease, which are notoriously difficult to measure and track in vivo. With the data they provide, physicians can more accurately fibrotic diseases, oncology, and related conditions, and drug developers can monitor treatment progression or regression, or stratify patients for clinical trials.